Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY

Inclusion Criteria:

Patients ages between 0 to and 65 years of age.
Patient must have a genotypically HLA-identical sibling, a phenotypically matched first-degree relative or an unrelated matched donor.
Acute lymphocytic leukemia (ALL) in CR1 with high risk features

Acute myeloid leukemia (AML) in CR1 with high risk features defined as:

i. Greater than 1 cycle of induction therapy required to achieve remission, ii. Preceding myelodysplastic syndrome (MDS) other than myelofibrosis, secondary AML iii. Presence of Flt3 mutations or internal tandem duplications, iv. FAB M6 or M7 classification or adverse cytogenetics for overall survival such as those associated with MDS, M6, M7 leukemia, or v. Complex karyotype [> 3 abnormalities]

Acute Leukemias in 2nd or greater remission
Refractory or Relapsed AML
AML transformed from MDS
Myelodysplastic syndrome (MDS) beyond refractory anemia
Chronic myeloid leukemia (CML)
Chronic myelomonocytic leukemia
Philadelphia-negative myeloproliferative disorder
Relapsed chemotherapy-sensitive Hodgkin's or Non-Hodgkin's lymphoma
Multiple Myeloma-Stage III

Exclusion Criteria:

Prior autologous or allogeneic stem cell transplant.
Performance status greater than 2
Active infection.
Inadequate cardiac function; arrythmias or symptomatic cardiac disease.
Inadequate pulmonary function; FEV1, FVC, DLCO <50% of predicted
Inadequate Serum creatinine clearance <60
InadequatebHepatic function
Positive serology for HIV-1, 2 or HTLV-1, 2.
Pregnancy. Female patient must have negative pregnancy test